Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Granulosa Cell Ovarian Cancer
National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Granulosa Cell Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Arimidex Memorial Sloan Kettering Cancer Center | Phase 2 | B |
BLEOMYCIN GOG Foundation | Phase 2 | CCC |
CIS-DIAMMINEDICHLOROPLATINUM II GOG Foundation | Phase 2 | CCC |
Carboplatin GOG Foundation | Phase 2 | CCC |
ETOPOSIDE GOG Foundation | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →